Sartorius Stedim Biotech S.A. reported unaudited earnings results for the fiscal 2012. For the fiscal 2012, the company reported sales revenue of EUR 544.0 million against EUR 477.3 million a year ago. EBITDA was EUR 118.6 million against EUR 99.6 million a year ago. EBITA was EUR 101.1 million against EUR 83.5 million a year ago. Mainly driven by economies of scale, underlying EBITA soared 21.0%. Net profit was EUR 64.5 million against EUR 53.4 million a year ago. Underlying earnings per share were at EUR 4.21, up from EUR 3.49 in 2011.

For 2013, the company projects sales revenue to grow by about 8% to 11% in constant currencies, which includes a gain of approx. 3% points resulting from the cooperation with the Swiss life science group Lonza in cell culture media. Along with growth in sales, the underlying EBITA margin is forecasted to rise to approx. 19%.